lenvatinib Mesylate CAS NO.857890-39-2

1,we produce and sell good chemicals around the world.
2,our success rate is about 95%. this means, if customer order is accepted, the probability that the customer will obtain the ordered substances, is 95%.
3,our staff consists of highly qualified individuals with bsc, msc and ph.d degrees in chemistry, as well as excellent carbohydrates,nucleosides, small molecules and rare chemicals.
4,imaginechem's chemists are skilled at performing complex, multi-step syntheses and solving difficult chemistry-related problems. because of our better, concentracted size and low overheads, we are able to offer prompt quotations, very competitive prices, high quality products and fast delivery.
5,all chemicals are typically >97% for building blocks, the structure and purity is confirmed by nmr and lc-ms. intermediates and final products are analyzed by gc, hplc, ir, nmr, ms, elemental analysis, atom-absorpting analysis and crystallographical methods.
165,Customers-oriented strategy, exclusive supply chain management, professional R&D team, experienced production workers, energetic sales team enable us to offer best service andgood-value products to all of our customers and gradually reach our final goals: becoming global leading supplier for portable products and solutions.

Product Name:    lenvatinib Mesylate
Synonyms:    lenvatinib Methanesulfonate;E7080 Mesylate;4-[3-Chloro-4-[[(cyclopropylamino)carbonyl]amino]phenoxy]-7-methoxy-6-quinolinecarboxamide monomethanesulfonate;4-[3chloro-4-(N'-cyclopropylureido)phenoxy]-7-methoxyquinoline-6-carboxamide methanesulfonate;CAT#A863437;Lenvatinib Mesylate,Amadis Chemical offer CAS#857890-39-2;lenvatinib Mesylate;E7080;E-7080;E 7080
CAS:    857890-39-2
form     Solid
color     White to Off-White
Description    Lenvatinib mesylate (lenvatinib) is an oral targeted therapy medicine known as a receptor‐type tyrosine kinase inhibitor. It is a small-molecule drug (a drug that can enter cells easily), which was developed at Eisai in 2015. It was approved by the FDA in 2015 for the treatment of differentiated thyroid cancer that is either locally recurrent, metastatic, or progressive and did not respond to radioactive iodine treatment. In May 2016, the FDA approved the drug as a combination therapy with everolimus for the treatment of advanced renal cell carcinoma. Because VEGF (and fibroblast growth factor receptors, known as FGFRs) are thought to play a role in cardiovascular signaling pathways, VEGF2R and FGFR inhibition are thought to be the mechanisms behind the primary side effect of lenvatinib mesylate, which is hypertension.